About Certis Oncology Solutions
Certis Oncology Solutions is a company based in San Diego (United States) founded in 2016 by James H Berglund. Certis Oncology Solutions has raised $13.65 million across 2 funding rounds. Certis Oncology Solutions offers products and services including CertisAI, Cancer Models, In Vitro Pharmacology, and In Vivo Pharmacology. Certis Oncology Solutions operates in a competitive market with competitors including Xentech, Nanoligent and Rincon Bio, among others.
- Headquarter San Diego, United States
- Founders James H Berglund
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Certis Oncology Solutions, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13.65 M (USD)
in 2 rounds
-
Latest Funding Round
$10 M (USD), Series C
Jan 17, 2024
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Certis Oncology Solutions
Certis Oncology Solutions offers a comprehensive portfolio of products and services, including CertisAI, Cancer Models, In Vitro Pharmacology, and In Vivo Pharmacology.
AI tool for oncology intelligence and data analysis in research
Custom development of cancer models for testing and pharmacology
Pharmacology testing for drug development in oncology studies
In vivo testing methods for cancer research and endpoint analysis
People of Certis Oncology Solutions
Unlock access to complete
Unlock access to complete
Funding Insights of Certis Oncology Solutions
Certis Oncology Solutions has successfully raised a total of $13.65M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $10 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Certis Oncology Solutions
Investment portfolio details for Certis Oncology Solutions
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Certis Oncology Solutions
Detailed financials for Certis Oncology Solutions
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Certis Oncology Solutions Comparisons
Peer comparison for Certis Oncology Solutions
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Certis Oncology Solutions
Certis Oncology Solutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Xentech, Nanoligent and Rincon Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Patient-derived xenograft models for preclinical oncology research are provided.
|
|
| Locked | Locked | Locked |
Preclinical services for oncology drug development are provided.
|
|
| Locked | Locked | Locked |
Pre-clinical CRO for in vivo cancer efficacy studies using xenograft and syngeneic models.
|
Detailed competitors of Certis Oncology Solutions
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Certis Oncology Solutions
Complete news archive for Certis Oncology Solutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Certis Oncology Solutions
Certis Oncology Solutions was founded in 2016 and raised its 1st funding round 7 years after it was founded.
Certis Oncology Solutions is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Certis Oncology Solutions is a funded company, having raised a total of $13.65M across 2 funding rounds to date.
Certis Oncology Solutions was founded in 2016 and is based in San Diego, United States. In-vivo services focused on oncology are offered to pharmaceutical and biotechnology companies. Certis Orthotopic PDX techniques, involving patient-derived orthotopic xenografts, are utilized to model human tumor growth, metastasis, and therapy responses. These services support drug development in the oncology sector.
Certis Oncology Solutions's top competitors include Nanoligent, Xentech and Rincon Bio.
Certis Oncology Solutions offers CertisAI, Cancer Models, In Vitro Pharmacology, and In Vivo Pharmacology.